Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | DRD1 | P21728 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | HTR3A | P46098 | 7/20 | 0.43 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | HTR7 | P34969 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33323 | 0.87 | DRD2 (0.51) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL17471629 | 0.85 | HTR3E (0.44) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| Hydrochloric Acid SCHEMBL7853611 | 0.85 | DRD2 (0.49) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL18639828 | 0.84 | DRD2 (0.41) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL10108539 | 0.84 | HRH4 (0.44) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL11929339 | 0.81 | DRD2 (0.35) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3411946 | 0.74 | DRD2 (0.82) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3413788 | 0.72 | DRD2 (0.67) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3413510 | 0.71 | DRD2 (0.70) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 | |
| SCHEMBL3414277 | 0.69 | DRD2 (0.78) | DRD2CYP1A2CYP3A4CYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3349760-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Coda Biotherapeutics, Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017049252-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | SWITCH BIO, INC. (US) | 2017-03-23 | — | — | WO | claimed |
| EP-3349760-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Coda Biotherapeutics, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180193414-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | CODA BIOTHERAPEUTICS INC (US) | 2018-07-12 | — | — | US | disclosed |
| WO-2017049252-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | SWITCH BIO, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-2288345-B1 | PSYCHO-PHARMACEUTICALS | UNIV DUBLIN (IE) | 2015-06-10 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007050697-A2 | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION PSYCHOTROPIC DRUGS WHICH MODULATE BODY WEIGHT | AZUR PHARMA III LIMITED (BM) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070092586-A1 | Compositions and methods for the administration psychotropic drugs which modulate body weight | ALAMO PHARMACEUTICALS (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070092586-A1 | Compositions and methods for the administration psychotropic drugs which modulate body weight | ALAMO PHARMACEUTICALS (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | DRD2 1837/4885CYP1A2 2055/4885CYP3A4 2764/4885 |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DRD2 1528/4885CYP1A2 4444/4885CYP3A4 4765/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | DRD2 1115/4885CYP1A2 4816/4885CYP3A4 4875/4885 |
| US-20070092586-A1 | Compositions and methods for the administration psychotropic drugs which modulate body weight | CYP2D6, HTR5A, HTR2A | DRD2 17/4885CYP1A2 33/4885CYP3A4 110/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | DRD2 4305/4885CYP1A2 4835/4885CYP3A4 4872/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | DRD2 1837/4885CYP1A2 2055/4885CYP3A4 2764/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DRD2 1528/4885CYP1A2 4444/4885CYP3A4 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.